Page last updated: 2024-10-24

positive regulation by host of viral genome replication

Definition

Target type: biologicalprocess

A process in which a host organism activates or increases the frequency, rate or extent of viral genome replication. [GOC:jl]

Positive regulation by host of viral genome replication is a complex biological process that involves a dynamic interplay between the host cell and the invading virus. It encompasses a range of cellular mechanisms that either directly or indirectly enhance the replication of the viral genome within the host cell.

Here's a detailed breakdown of the process:

1. **Viral Entry and Uncoating:** The process begins with the virus attaching to and entering the host cell. This entry can occur through various mechanisms like endocytosis, fusion, or direct penetration. Once inside, the viral capsid disassembles, releasing the viral genome into the host cell's cytoplasm.

2. **Host Transcription Factors:** A key aspect of positive regulation involves the recruitment of host transcription factors. These factors bind to specific DNA sequences within the viral genome, promoting the transcription of viral genes. This transcription process involves the synthesis of messenger RNA (mRNA) from the viral DNA.

3. **Host Ribosomes:** The synthesized viral mRNA then interacts with host ribosomes. These ribosomes are responsible for translating the mRNA into viral proteins, essential for viral replication and assembly.

4. **Host Replication Machinery:** Viruses lack their own replication machinery. Instead, they rely on the host cell's enzymatic machinery to replicate their genomes. This includes DNA polymerases, RNA polymerases, and other enzymes that are normally involved in host cell DNA and RNA replication.

5. **Host Cell Resources:** Viral replication is a resource-intensive process, requiring the host cell to divert its resources, like nucleotides, amino acids, and energy, towards the synthesis of new viral components.

6. **Host Protein Modification:** The host cell also plays a role in modifying viral proteins. This modification often includes phosphorylation, glycosylation, or ubiquitination, which can alter the function and stability of these proteins.

7. **Viral Assembly and Release:** Once new viral components are synthesized, they assemble into new viral particles. These particles can then bud off from the host cell, carrying the viral genome to infect other cells, perpetuating the cycle of infection.

In some cases, the host cell may also exhibit specific cellular responses that can either enhance or inhibit viral replication. For instance, the host cell might activate immune signaling pathways that lead to the production of antiviral proteins, which can interfere with viral replication. Alternatively, the host cell might promote the expression of genes that are beneficial for viral replication.

It's important to note that this is a simplified overview of a complex process. The exact mechanisms and host factors involved can vary significantly depending on the specific virus and the host cell type. However, the overall principle of positive regulation by the host remains the same: the host cell, in a complex interplay of events, provides the necessary components and environment for the virus to replicate its genome, eventually leading to the production of new virus particles.'
"

Proteins (3)

ProteinDefinitionTaxonomy
Phosphatidylinositol 3-kinase catalytic subunit type 3A phosphatidylinositol 3-kinase catalytic subunit type 3 that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)
Peptidyl-prolyl cis-trans isomerase BA eukaryotic peptidyl-prolyl cis-trans isomerase B that is encoded in the genome of human. [PRO:DNx, UniProtKB:P23284]Homo sapiens (human)
Heat shock cognate 71 kDa proteinA heat shock cognate 71 kDa protein that is encoded in the genome of human. [PRO:DAN]Homo sapiens (human)

Compounds (37)

CompoundDefinitionClassesRoles
adenosine diphosphateAdenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate
fundamental metabolite;
human metabolite
tubercidintubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.

Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside
antimetabolite;
antineoplastic agent;
bacterial metabolite
toyocamycintoyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.

Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside
antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
nsc 65346sangivamycin : A nucleoside analogue that is adenosine in which the nitrogen at position 7 is replaced by a carbamoyl-substituted carbon. It is a potent inhibitor of protein kinase C.

sangivamycin: RN given refers to parent cpd
nucleoside analogueprotein kinase inhibitor
adenosinequinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlitadenosines;
purines D-ribonucleoside
analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
prolinalpyrrolidines
8-aminoadenosine
5'-deoxyadenosine5'-deoxyadenosine : A 5'-deoxyribonucleoside compound having adenosine as the nucleobase.

5'-deoxyadenosine: main heading DEOXYADENOSINE refers to the 3' cpd
5'-deoxyribonucleoside;
adenosines
Escherichia coli metabolite;
human metabolite;
mouse metabolite
ML162ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells.monochlorobenzenes;
monomethoxybenzene;
organochlorine compound;
secondary carboxamide;
tertiary carboxamide;
thiophenes
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer
cyclosporineramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MFhomodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
(melle-4)cyclosporin(melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A
scy-635
PI3-Kinase alpha Inhibitor 2organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
alisporiviralisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first sourcehomodetic cyclic peptideanticoronaviral agent
idelalisibidelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.

idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source
aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zstk474ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
dactolisibdactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.

dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR
imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
ku 60019
buparlisibNVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first sourceaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
gdc 0941pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ver 155008VER 155008: structure in first sourcepurine nucleoside
gdc 0980
azd2014vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source
pki 587gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-aminesapanisertib: an mTOR inhibitorbenzoxazole
ch 5132799CH 5132799: structure in first source
torin 1torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
gdc-0032
spautin-1
torin 2torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline
antineoplastic agent;
mTOR inhibitor
cudc-907
sar245408
byl719proline derivative
amg 511AMG 511: structure in first source
cc-223
sar405SAR405: a Vps34 inhibitor with antineoplastic activity; structure in first source
nms-e973NMS-E973: structure in first source